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INTRODUCTION
 Transgender individuals have gender identity, gender expression, 
or behavior that differs from their biological sex assigned at birth.1 It 
is estimated that 0.3% of US adults identify as transgender, which is 
nearly 1 million people.2  While much is unknown in the field of gender 
incongruence, “a growing and persuasive body of evidence suggests 
that biological factors have a substantial role in predisposing some 
people towards gender incongruence”.2
 The earliest recognition of gender nonconformity in Western 
medicine was in the 1920’s and was labeled as a mental pathology.3 
Gender Identity Disorder (GID) became a diagnosis in the American 
Psychiatric Association’s third edition of the Diagnostic Manual of 
Mental Disorders (DSM) in the 1980s. GID was a mental pathology 
until the DSM-54 was released in 2012, when GID was dropped as 
a diagnostic condition. Now, the DSM-54 has only an overarching 
diagnosis of gender dysphoria. This newly defined diagnosis does not 
pathologize being transgender, instead it can occur when an individual 
who is transgender has distress related to the incongruence between 
his/her experienced and expressed gender. Psychological treatment 
targets coexisting emotional and mental morbidities. Thus, the trend 
has shifted from attempting to treat gender nonconforming individu-
als to being more accepting of them.2
 To that end, this overview addresses what it takes to be a competent 
transgender provider, including knowing health needs, health dispari-
ties, and health coverage. Next, medical biases toward transgender 
patients are examined and current hormone treatment guidelines 
are outlined for both transgender men and women. Also, treatment 
options for transgender children and adolescents, along with aging 
patients, are discussed. The discussion concludes with trends, move-
ments, and expectations for medical curricula.
Health Needs
 Besides being a social minority, transgender individuals are a 
health minority who face myriad challenges as outlined in the Nation-
al Transgender Discrimination Survey.5 The challenges outlined in 
the survey include facing serious acts of discrimination, such as loss 
of job, eviction, bullying, physical or sexual assault, denial of medical 
services, and incarceration. Barriers faced by transgender people 
in society and in the medical system make this group more likely to 
experience mental illness, discrimination, and poor health outcomes.3 
For example, prevalence of psychiatric diagnoses appears to be high, 
especially for lifetime depressive episode estimated at 35.4%, and sui-
cidality for transgender women at 20.2%.6
 Along with traditional health care, transgender individuals have 
unique needs related to gender transitioning, specifically mental 
health, hormonal treatment and side effects, and adequate referral to 
surgery, which can “create an undesired and unavoidable dependency 
on the medical system.”3 Procedures may include facial feminization/
masculinization surgery, voice, breast, or chest surgery, hysterecto-
my, and genital reconstruction.7 Patients who experience obstacles 
in obtaining health services may experience short- and long-term 
negative health consequences. Of particular concern, one in four 
transgender women self-prescribe cross-sex hormones and obtain 
them illegally (most commonly via the internet), a practice that may 
be hazardous to health.8 This practice rarely was observed for trans-
gender men.
Health Disparities
 Healthy People 2020 outlines the need to research factors con-
tributing to health disparities in the Lesbian, Gay, Bisexual, and 
Transgender (LGBT) community.9 A survey was conducted in 2008 
by the National Center for Transgender Equality and the National 
Gay and Lesbian Task Force to understand these health disparities.5 
Participants included 7,500 individuals. Results showed that 19% of 
respondents reported being denied health care based on their gender 
identity, and 28% reported verbal harassment in a medical setting. 
A third of respondents avoided preventive care, while 28% reported 
postponing any medical care due to discrimination and disrespect. 
Findings showed a higher than average likelihood of human immu-
nodeficiency virus (HIV) among transgender patients. Respondents 
also were more likely to depend on drugs and alcohol to cope with 
negative experiences, while a higher likelihood of lifetime suicide 
attempts was revealed: 41% compared with 1.6% in the general popu-
lation. This percentage was for both male and female respondents. 
Racial minorities who are transgender appeared to experience the 
highest risk for negative health outcomes and risk-taking behaviors.
 Almost ten years later, the National Transgender Discrimination 
Survey was conducted with 6,450 transgender and gender non-con-
forming participants.5 Experiences of discrimination where equal 
treatment was denied was reported by 24% of participants in doctor’s 
offices or hospitals, 13% in emergency rooms, 11% in mental health 
clinics, and 5% for ambulance or emergency medical services. Par-
ticipants also reported being harassed or disrespected at even higher 
rates for these same locations. 
 Results of these studies, among others, led the Association of 
American Medical Colleges (AAMC) to conclude that transgender 
health needs are not addressed adequately, and education for medical 
providers and staff about transgender health and cultural competen-
cies is necessary. Thus, they convened an advisory committee in 2012 
to develop a set of competencies for undergraduate medical educa-
tion.10
Health Coverage
 In 2011, the Veterans Health Administration in the US 
Department of  Veterans Affairs (VA) issued directives to support cov-
ering medical care and hormonal treatment for transgender patients.
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argument it comprises genital alteration, which is excluded from 
veterans’ medical benefits packages. Statements from the current 
Directive 2013-003, which expires on Feb. 28, 2018, are:
1) Establishes policy regarding the respectful delivery of health 
care to transgender and intersex veterans.
2) Provides health care for transgender patients, including 
those who present at various points on their transition from one 
gender to the next.
3) Medically necessary care is provided to enrolled or otherwise 
eligible intersex and transgender veterans, including hormonal 
therapy, mental health care, preoperative evaluation, and medi-
cally necessary post-operative and long-term care following sex 
reassignment surgery. 
But, the directive explicitly stated that SRS cannot be performed or 
funded by the VA.11
 Many private insurance companies have included hormonal treat-
ment, except Medicaid, unless a letter of medical necessity and the 
terminology “hormonal replacement” are used.12 Coverage is expected 
to change in favor of hormonal treatment, given a 2012, US Depart-
ment of Health and Human Services (HHS) statement clarifying that 
the ban on sex discrimination in section 1557 (nondiscrimination) 
includes discrimination based on gender identity.13 Further, on May 
30, 2014, the US HHS Departmental Appeals Board determined the 
National Coverage Determination denying coverage for all trans-
sexual surgery was not valid. As a result, Medicare Administrative 
Contractors determine coverage on a case-by-case basis.12
 Treatment appears to alleviate gender dysphoria and have posi-
tive effects on quality of life.14,15 However, a scoping review observed 
that many published articles on the sexual health of transgender 
men come from limited data with potentially biased samples, citing 
controversial recruitment practices and high dropout rates, which 
may inflate the positive effects of therapy.16 In addition, a systematic 
review stated a need for new self-assessment tools to evaluate func-
tional, psycho-relational, cosmetic, and quality of life of patients who 
undergo transsexual surgery.17
 Despite increased efforts to support transgender health, linking 
medical care to transition care remains the most common cause of 
coverage denial. Perhaps insurers will agree to enhance coverage after 
more research is conducted (with less biased samples and new evalu-
ation tools) that verify the benefit of SRS. 
Medical Biases toward Transgender Patients
 Transgender individuals experience many barriers to healthcare.18 
Among these were: 1) fear of being seen as different (with associated 
stigma and violence), 2) lack of access to caring and competent pro-
fessionals, 3) difficulty in identifying sources of information about 
gender dysphoria and hormone therapies, and 4) inadequate access 
to safe prescribing and monitoring of hormone therapy. One of the 
most commonly reported barriers to healthcare identified by trans-
gender individuals is their ability to find a knowledgeable provider.19 
Fifty percent of transgender patients reported having to educate their 
providers about transgender health in a 2014 survey.20 
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 Medical school and residency curricula are lacking in transgender 
health.18 Culturally competent language and sensitive approaches to 
transgender individuals are lacking from most medical training.21 In 
2014, only one third of US medical schools had any teaching or train-
ing in transgender health, and the ones that did may not be adequate 
to ensure enough knowledge to make providers comfortable to treat 
transgender patients.22 One theory for the discrepancy between 
patient need and medical availability is the belief among medical pro-
viders that transgender patients suffer from a psychological disorder. 
Although the DSM-54 has changed the terminology around transgen-
derism, it has kept it as a diagnosable condition that can occur when 
an individual who is transgender has distress related to the incongru-
ence between his/her experienced and expressed gender.21
 A growing body of research indicates that gender identity can be 
independent of chromosomal findings.15 Transgender patients’ brains 
correlated with physical manifestations of gender identity. Male 
transgender individuals’ brains showed white matter microstruc-
ture more similar to cisgender males than cisgender females. Female 
transgender individuals without hormonal treatment had brain char-
acteristics similar to cisgender females (e.g., size of the bed nucleus 
of the stria terminalis in the hypothalamus within the female range). 
In summary, individuals with a certain gender identity have anatomic 
brain findings consistent with their preferred biological sex, despite 
the sex assigned to them at birth.
Standards of Care
 Standards of care (SOC) have been developed by the World Pro-
fessional Association for Transgender Health (WPATH).23 WPATH 
standards include primary care, gynecologic and urologic care, repro-
ductive options, voice and communication therapy, mental health 
services, along with hormonal and surgical treatments. A WPATH 
Mobile App is available at Google Play and iOS at the iTunes Store. 
The guideline from the Center of Excellence for Transgender Health 
complements WPATH, and is designed for implementation in every 
day evidence-based primary care settings.
Hormonal Regimen for Transgender Men
 Transgender males are assigned female sex at birth, but self-identify 
as male.15 Their hormonal treatment consists of administering testos-
terone to achieve maximum virilization. The levels are increased by 
pharmacological administration (intramuscular or patch) until the 
measured testosterone levels are within the normal male range (300 
- 1000 ng/dl). Testosterone can be administered orally, however, that 
preparation is not available in the US. The most commonly used form 
in the US is intramuscular with doses of 50 - 200 mg weekly. Patients 
can go to bi-weekly dosing and administer higher doses (100 - 200 
mg intramuscular) themselves, but the levels of testosterone fluctuate 
more with a bi-weekly regimen. Transdermal preparations (patch of 
2.5 - 7.5 mg daily), testosterone 1% gel (2.5 - 20g/day), or intramus-
cular testosterone work, but may cause skin irritation and virilizing
16
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side effects to family members contaminated with the gel or cream if 
patients are not careful. 
 Transgender men must be followed initially every three months to 
check for virilizing and side effects.15 The main effects observed are 
loss of periods (amenorrhea), increased facial and body hair, increased 
muscle mass with changed fat distribution to male pattern, increased 
acne, and increased libido. Deepening of the voice, enlarged clitoris 
(clitoromegaly), and male pattern hair loss occur to varying extent in 
different individuals and occur over the first year. Transgender men 
starting hormonal treatment after the age of 40 may see less virilizing 
effects.
Follow-up and Side Effects 
 Transgender males require follow-up every three months over the 
first year, then every six months the following year and yearly, if lab 
tests are within acceptable limits.15 Testosterone levels are obtained at 
every visit; the dose can be modified to achieve a level in the male range 
(300 - 1000 ng/dl). Hematocrit and lipid levels are monitored. A bone 
scan is obtained at the beginning of treatment if patients are at risk of 
osteoporosis or not achieving adequate levels, otherwise the bone scan 
screening starts at age 60. Transgender males with breast tissue and 
cervixes need appropriate screening.
 Transgender males on testosterone will have reduced fertility and are 
less likely to get pregnant.15 Those effects are permanent even with stop-
ping testosterone. Pregnancy is possible and that should be explained 
to transgender males who engage in sexual activity with partners with 
sperm (fertile non-transgender men or fertile transgender women). 
Transgender men are also at the risk of contracting sexually transmit-
ted infections with unprotected sex.
Hormonal Regimen for Transgender Women
 Transgender women born with male biologic sex require a block-
age of testosterone action (anti-androgen) besides increasing estrogen 
levels.15 Treating transgender women aims at decreasing testosterone 
to the female range (30 - 100 ng/dl) and obtaining an estrogen level not 
exceeding the physiological female range (< 200 pg/ml). Treating with 
anti-androgens, such as spironolactone, allows for lower doses of estro-
gen. Spironolactone is used orally in a dose of 100 - 200 mg daily, but 
may be used up to 400 mg if needed. Spironolactone is a mild potassium 
sparing diuretic, hence the need to monitor levels of potassium. Estro-
gen is administered orally (2.5 - 7.5 mg of estrogen or 17-beta estradiol 
at 2 - 6 mg) daily or intramuscularly (estradiol valerate 2 - 10 mg once 
a week or 5 - 20 mg every two weeks). Patches can be used (estradiol 
patch 0.1 - 0.4 mg, two times a week) if the transgender woman is at 
increased risk of thromboembolic disease. 
Changes
 Body hair decreased, skin was less oily, muscle mass decreased with 
redistribution of body fat in a female pattern, spontaneous erections 
decreased, and libido and breast development decreased within three 
to six months. Breasts reached peak size typically after two years of 
hormonal treatment.15
Monitoring and Side Effects
 Transgender women on hormonal treatment must be monitored 
with testosterone levels (suppressed to 30 - 100 ng/dl) and estradiol 
levels increased but remaining below 200 pg/ml.15 They also must be 
monitored for potassium levels due to the risk of having high levels with 
testosterone-blocking spironolactone. The levels of prolactin and tri-
glycerides need checked with labs, since estrogen treatment may cause 
hyperlipidemia.
Transgender Children and Adolescents
 Many pre-pubertal patients with varying features of gender dyspho-
ria will become transgender teenagers.18 Most transgender teenagers 
experience gender identity conflicts as children. Children who identify 
with a gender different from one assigned at birth often become gay and 
lesbian adults and do not become transgender adolescents. The child’s 
reaction to beginning puberty is often diagnostic. The guidelines recom-
mend allowing puberty to start without medical intervention, however, 
if not desired, puberty can be blocked early on (at Tanner stages 2 and 
3), and hormonal treatment started when the patient is deemed ready 
(age 18 or 16 with parental consent). Puberty suppression is done for 
patients who are non-transgender with precocious puberty to avoid 
permanent short stature. Some medical professionals are familiar with 
puberty blockage, however, not for transgender patients. The trend for 
transgender health awareness and education targets this gap area to 
keep transgender teenagers from going through the “wrong puberty”. 
 Puberty suppression for teenage transgender individuals reduces the 
risk of emotional and behavioral problems and increases functioning.18 
A study of a simple one-hour transgender curriculum at a Boston Uni-
versity Medical School showed improved student willingness to treat 
transgender patients, and increased perceived knowledge and comfort 
level.19
Assessment of a Teenager with Gender Dysphoria
 Whereas the majority of preadolescent individuals seeking medical 
attention for gender dysphoria are born with male gender and identify as 
girls, the ratio in adolescence is close to a ratio of 1:1.24 One explanation 
for transgender girls attracting parental and medical attention is that 
society is more accepting and less alarmed about female-born individu-
als who dress and act in a masculine fashion. “Tomboy” is a term used 
for those individuals with no equivalent for their male-born counter-
parts. Regardless of when gender dysphoria manifests, the consistency, 
persistence, and insistence of a teenager with an identified gender that 
is not the one assigned at birth should be taken seriously. Suicidal ide-
ation, depression, and self-medication increase remarkably at this age.21 
Ideally, a multidisciplinary team with a psychologist, social worker, and 
physician are available for those patients and families. It often is not the 
case and many teenage transgender patients avoid medical care and 
some will attempt conforming to their birth gender, typically without 
success, and many secondary emotional consequences. 
 A medical provider lacking the sensitivity and cultural competence 
to engage a transgender patient, especially a teenager, will miss signs 
of gender dysphoria and potentially cause harm by saying gender ste-
reotypical things that alienate the patient further.22 Medical providers 
interacting with teenagers should establish a safe space and inform 
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suicidal intentions. Once patients feel safe to discuss private matters, 
they likely will be willing to talk about any gender struggles they may be 
experiencing.
 Competent clinicians who provide care for teenage patients are 
expected to screen for emotional and social stressors as part of an 
interview during their yearly well check. If an adolescent discloses 
concerns about gender, the clinician should be able to screen for 
gender dysphoria and be prepared to suggest resources to help the 
patient and their family. A mental health clinician is often the first 
place to obtain a diagnosis and suggest future steps. Gender dysphoria 
screening is not recommended in every teenage patient who is not 
gender conforming, but should be screened for well-being and per-
sonal struggles. 
 Once a clear and consistent gender identity is established and 
mental health providers, family, and patient agree on treatment 
regimen, hormonal replacement can start.18 Ideally, puberty would 
have been blocked and minimal secondary sexual characteristics of 
the birth gender are present. Puberty blockage usually is done with 
gonadotropin-releasing hormone (GnRH) analogues. Patients must 
be monitored with bone scans, as height and bone density growth 
slows during treatment with GnRH analogues. Puberty blockage 
allows for the need to use fewer hormones to establish the desired 
secondary sexual characteristics (facial hair, deep voice, and male 
body habitus in transgender females; breast development and female 
body habitus in male transgender) and has been correlated with less 
psychosocial negative outcomes in transgender teens. Progestins 
are used in the transgender male teenager to avoid menstruation 
and cyproterone can suppress erections and nocturnal emissions in 
female transgender teenagers. However, the latter medication can 
cause breast tissue development and is not recommended without 
ensuring that the transgender identity is well established for the teen-
ager.
 Parental or legal guardian consent is necessary in treatment for 
transgender teenagers.17 Consent is a problem for many teenagers 
with unsupportive families and has been associated with maladaptive 
behaviors, such as running away from home, and risky, self-destructive 
behaviors. Visibly gender non-conforming teenagers are vulnerable to 
harassment and hate crimes. The options of teenage transgender indi-
viduals are limited by their financial dependence on their families and 
abilities to become financially independent. Homeless transgender 
teenagers have a challenge in finding housing options, as they often 
are placed based on the gender of their birth. 
Aging Transgender Guidelines for Screening and Preventative 
Health
 Hormonal replacement has no age limit. However, transgender 
males who stop testosterone lose their facial and body hair, muscle 
mass, suffer from decreased libido, and develop hot flashes.15 It is not 
recommended to stop hormones if the patient has had resection of 
their birth gonads (post-gonadectomy) because both men and women 
are at risk of bone loss and symptoms similar to post menopause. 
Osteoporosis has been reported in both transgender men and women 
with poor hormone regimen. Surgical confirming procedures carry a 
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higher risk for older patients, as do most major surgical procedures, 
and those risks should be discussed with the surgeon (surgical team) 
involved with gender confirmation surgery.25
 Transgender females on feminizing treatment should be screened 
for breast cancer if they have been on estrogen for 30 years and 
are older than 50.15 If those women have a strong family history of 
breast or ovarian cancer, screening should begin earlier. Screening 
is done with mammography. Yearly breast exams and self-exams for 
transgender women without family history of breast cancer are not 
recommended. Breast augmentation does not increase transgen-
der women’s risk of breast cancer, but may reduce the accuracy of 
mammography. Transgender women with prostate tissue should be 
screened with an exam for enlarged prostates, if they develop symp-
toms. Prostate-specific antigen is not a useful marker for transgender 
women on estrogen. Transgender women with prostates must be 
screened for prostate cancer and breast cancer. Feminizing hormones 
increase the risk of venous thromboembolic disease, cardiovas-
cular disease, hypertension, and prolactinomas (which is when an 
adenoma, or a non-cancerous tumor, of the pituitary gland overpro-
duces the hormone prolactin). More studies are necessary to clarify 
these increased risks.
 Transgender males with a cervix need pelvic exams every one 
to three years after the age of 40.15 Transgender men may not have 
engaged in vaginal penetrative intercourse and examining the vagina, 
cervix, and uterus may be traumatic. It is recommended to delay those 
parts of the exam until a good connection is established between the 
patient and the examiner and the patient indicates readiness. Sedation 
can ease the exam and make it less painful. If the patient cannot toler-
ate pelvic exams, hysterectomy and oophorectomy are recommended. 
Transgender males over the age of 60 and taking testosterone for over 
five years need bone scans. If transgender males have been on testos-
terone over five years and they have other risks of osteoporosis, they 
should test at age 50. Calcium and vitamin D are recommended for 
transgender males due to the unknown effect of testosterone on bone 
density.
 All transgender individuals should be screened for cardiovascu-
lar health.15 Cardiovascular risk factors should be decreased to a 
minimum before masculinizing or feminizing hormonal therapies. 
If a patient is at a high risk for cardiovascular disease, a stress test is 
indicated before treatment and when hormonal treatment is initiated, 
the patient should begin a low dose aspirin regimen. Patients should 
be screened for hypertension the same as the non-transgender patient 
population and blood pressure should be optimized to a goal of 130 
mmHg systolic or less and 90 mmHg diastolic or less. Blood pressure 
should be monitored every one to three months after the onset of tes-
tosterone in the first year in transgender men on hormones, especially 
in ones with Polycystic Ovary Syndrome (PCOS). Transgender men 
and transgender women should have a lipid profile check annually. 
High cholesterol should be treated to a level of 3.5 mmol/L in patients 
18
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with no risk factors and 2.5 mmol/L in those with additional cardiac 
risk factors. Patients taking estrogen have a higher risk of type 2 dia-
betes if a family history of diabetes occurs or a weight gain of over 11 
pounds. Transgender women should be screened annually with fasting 
blood sugar. For transgender men, screening is indicated with history 
of PCOS, otherwise diabetes screening guidelines are the same as 
those of the general population.
 All transgender individuals with risk behaviors for sexual trans-
mitted infections or blood transmitted infections (unprotected 
penile-vaginal or penile-anal intercourse, sharing needles) should 
be screened for HIV and Hepatitis B and C every six months.15 For 
transgender patients without those risk behaviors, screening once in 
a lifetime is recommended. All transgender patients need Hepatitis B 
vaccinations. All transgender patients should be screened for depres-
sion (e.g., Patient Health Questionnaire) and, if the screen is positive, 
referred to a transgender competent mental health provider.
Trends, Movements, and Expectations
 Despite the growing evidence supporting the value of treating 
transgender patients in a mindful, supportive setting, the transgen-
der health curriculum in most medical provider curricula remains 
unchanged. The AAMC has incorporated transgender educational 
material on MedEdPORTAL (https://www.mededportal.org/collec-
tions) with over 100 articles, presentations, and tools. Hospitals lack 
transgender policies and the medical environment remains a haunting 
experience for many transgender individuals. Health care provider 
attitudes toward transgender patients show bias and lack of perceived 
knowledge to treat them. 
 The transgender health movement is young, yet showing positive 
changes in health care learners when proper exposure and education 
take place.22 Although there remains a lack of medical education pro-
grams for transgender health, research supports introducing this topic 
early during clinical education of clinicians.13 Until transgender health 
care and cultural competence are mandated in medical curricula, the 
multiple significant obstacles remain facts in the health of over one 
million transgender people.5 
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